Standard GLP-1 contraindications still apply Compounded semaglutide has safety risks and contraindications to consider: Semaglutide is not indicated for patients with a personal or family history of thyroid tumors, particularly medullary thyroid carcinoma (MTC) and neuroendocrine tumors such as MEN 2 (multiple endocrine neoplasia) type 2 syndrome
No funding has been received for the preparation of this manuscript
These differences likely reflect local tissue binding, lymphatic uptake, and first-pass metabolism variations between administration sites and species
with documented symptomatic hypoglycemia occurred in 17.3% and 24.4% of patients when semaglutide 0.5 mg and 1 mg, respectively
But do they actually work
Published literature and reviews often describe BPC-157 as a peptide of interest in tendon, ligament, muscle, bone, and gastrointestinal healing models